Eli Lilly has raised its revenue guidance ... In its update, Ricks said a new facility at Concord in North Carolina – part of an $18 billion investment programme launched in 2020 – is being ...

Concord has acquired a portion of songwriter ... Born and raised in Gastonia, North Carolina, Davis is a country artist whose journey to Nashville is as unique as his sound.

Cabarrus is generally a pretty affluent and prosperous county, especially compared with many of the other counties across North ... Eli Lilly, which first broke ground on its state-of-the-art ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

During the last three months, 7 analysts shared their evaluations of Eli Lilly LLY, revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.